The vaccine targets a protein found at elevated levels in about 90% of the most common type of ovarian cancer. If validated in human studies, researchers believe the vaccine may be particularly useful for women who carry BRCA1 and BRCA2 gene mutations.
http://ift.tt/2iqGOvc
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου